MarketPeel
Insider Trading Intelligence
Pricing
…
EL

Erick Lucera

BBLG
DIRECTOR · BONE BIOLOGICS CORP · CIK 0001697616
FILING MIX · LIFETIME69%/31%
BUYS
37
SELLS
17
TOTAL VALUE
$348.1K
COMPANIES
5
ACTIVE SINCE
Feb 2021
HOLDINGS NOW
427,326
AVG SELL PX
$8.72
TRADE KIND
SHOWING 54 / 54
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Erick Lucera, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+60.00%-2.04%+0.45%-2.48%-3.58%—
14d5+60.00%-3.09%+1.73%-4.81%-1.57%—
30d5+80.00%-11.03%+2.93%-13.96%-13.90%—
60d5+40.00%-9.71%+3.73%-17.56%-17.99%—
90d5+40.00%-0.28%+8.59%-8.87%-2.49%—
180d5(1 pending)+50.00%-12.34%+12.19%-24.52%-32.78%—
1y5(1 pending)+25.00%-48.54%+20.80%-69.34%-87.15%—
2y5(3 pending)+50.00%-74.29%+43.96%-118.25%-118.25%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BBLG · 85,763 shares · as of Sep 18, 2023
021,44142,88264,32285,76320222023SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 37 buys / 17 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,362$20.37$48.1K121,563Jun 25, 2026Jun 26, 2026 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,448$18.36$26.6K123,925May 13, 2026May 14, 2026 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,727$18.64$106.8K125,373Apr 1, 2026Apr 3, 2026 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
105,000——105,000Feb 12, 2026Feb 17, 2026 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
65,000——131,100Feb 12, 2026Feb 17, 2026 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Dec 16, 2025Dec 18, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
3,750——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
1,250——1,250Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
3,750——3,750Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
1,000——1,000Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
2,000——2,000Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
2,250——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
1,500——1,500Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
2,250——2,250Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
2,000——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
1,250——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
1,000——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
1,500——0Nov 4, 2025Nov 6, 2025 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
214,500——214,500Mar 31, 2025Apr 1, 2025 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
66,100——66,100Mar 31, 2025Apr 1, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
75,000——75,000Mar 26, 2025Mar 28, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
275,100——275,100Mar 8, 2025Mar 27, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
70,000——70,000Mar 8, 2025Mar 27, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
4,109$1.71$7.0K112,720Mar 4, 2025Mar 5, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
30,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
40,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
45,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
25,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
20,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASE
39,266$0.40$15.6K43,608Aug 14, 2024Aug 15, 2024 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Jul 15, 2024Jul 17, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
22,337$5.61$125.4K116,829May 20, 2024May 22, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Mar 20, 2024Mar 21, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
106,000——106,000Mar 2, 2024Mar 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
35,300——113,200Mar 2, 2024Mar 5, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
25,966——139,166Mar 2, 2024Mar 5, 2024 ↗View →
BBLG
BONE BIOLOGICS CORP
PURCHASEGRANT
Stock grant
85,763——85,763Sep 18, 2023Sep 20, 2023 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
155,800——155,800May 17, 2023May 18, 2023 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
77,900——77,900May 17, 2023May 18, 2023 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Apr 3, 2023Apr 5, 2023 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Mar 29, 2023Mar 31, 2023 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASE
2,000$6.82$13.6K4,342Mar 16, 2023Mar 20, 2023 ↗View →
BBLG
BONE BIOLOGICS CORP
PURCHASEGRANT
Stock grant
36,845——68,516Aug 23, 2022Mar 7, 2023 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Mar 3, 2022Mar 7, 2022 ↗View →
BBLG
BONE BIOLOGICS CORP
PURCHASEGRANT
Stock grant
8,722——31,671Jan 1, 2022Feb 28, 2022 ↗View →
BBLG
BONE BIOLOGICS CORP
PURCHASEGRANT
Stock grant
2,949——22,949Oct 26, 2021Feb 28, 2022 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Mar 4, 2021Mar 8, 2021 ↗View →
XAIR
BEYOND AIR, INC.
SALE
1,171——0Feb 16, 2021Mar 3, 2021 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASE
1,171$4.25$5.0K2,342Feb 16, 2021Mar 3, 2021 ↗View →
Other insiders · BBLG
Loading peer insiders…
About this filer
CIK 0001697616
ROLE
Director
PRIMARY
BBLG
COMPANIES
5
ACTIVE SINCE
Feb 2021
MARKETPEEL · /INSIDER/0001697616DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback